XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Tables)

Condensed Consolidated Financial Statement Detail (Tables)

3 Months Ended

Mar. 31, 2022

Accrued and other liabilities consisted of the following (in thousands):


	March 31,		December 31,
	2022		2021
Accrued legal and accounting fees		445		295
Accrued incentive compensation		231		55
Accrued payroll and benefits		129		135
Other accrued liabilities		50		40
Total	$	855	$	525

Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net (Loss) per Share Available to Common Stockholders

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):


	Three Months Ended March 31,
	2022		2021
Numerator
Net loss	$	(2,280)	$	(7,373)
Less: Series A accumulated dividends		(530)		(530)
Less: Series B accumulated dividends		(838)		—
Net loss available to common stockholders, basic and diluted	$	(3,648)	$	(7,903)

Denominator
Weighted average shares used in computing basic and diluted net loss per share available to common stockholders		11,330		11,240
Basic and diluted net loss per share available to common stockholders	$	(0.32)	$	(0.70)

Outstanding Securities Considered Anti-Dilutive

The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):


	Three Months Ended March 31,
	2022	2021
Convertible preferred stock	5,003	5,003
Common stock options	697	277
Warrants for common stock	6	5
Total	5,706	5,285